Literature DB >> 32999886

Cohort Profile: The Christchurch IBS cOhort to investigate Mechanisms FOr gut Relief and improved Transit (COMFORT).

Phoebe Heenan1, Rob H Creemers1, Shriya Sharma1, Jacqueline Keenan2, Simone Bayer1, Wayne Young3,4,5, Janine Cooney5,6, Kelly Armstrong3, Karl Fraser3,4,5, Paula M Skidmore1, Nicholas J Talley7, Nicole Roy4,5,8, Richard B Gearry1,5.   

Abstract

BACKGROUND AND AIMS: This cross-sectional observational case-control study was initiated in July 2016 with the aim of increasing an understanding of the underlying disease mechanisms in functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS), functional diarrhoea (FD), and functional constipation (FC). Specific areas of interest include the effect of food, microbiome, host and microbial genetics, metabolome, and psychological variables on unexplained chronic gastrointestinal (GI) symptoms.
METHODS: This study recruited consecutive patients who were attending one of two endoscopy centres in Christchurch, New Zealand, for colonoscopy and a subgroup of participants from the general public who did not undergo colonoscopy. Participants with known GI disease other than an FGID were excluded. Those with symptoms were recruited as cases, whilst those without symptoms were recruited as controls. In the days prior to preparation for colonoscopy, or an agreeable time for those not undergoing colonoscopy, demographic, symptom, psychological, dietary, and health data were collected in addition to biological samples (breath, faeces, blood, and urine). Colonic biopsies were taken at the time of colonoscopy from participants in the colonoscopy subgroup.
RESULTS: Between July 2016 and December 2018, 349 participants were recruited, 315 of whom completed the study, 220 participants were from the colonoscopy subgroup, and 95 from the non-colonoscopy subgroup. This included 129 controls and 186 cases (57 IBS-diarrhoea predominant, 30 IBS-constipation predominant, 41 IBS-mixed, 42 FC, and 16 FD). The mean age of FGID cases was 53.4 years and controls 54.4 years. Cases (149/186, 80.1%) and controls (57/72, 55.8%) were predominantly female. Education levels were similar across the cohort. Smoking and alcohol rates were also similar. Biological samples were collected as planned from participants.
CONCLUSIONS: The COMFORT cohort is a unique clinical cohort of FGID cases and controls with a wide range of demographic, dietary, clinical, psychological, and health data in addition to biological samples. Future research will aim to use a systems biology approach to establish the potential role of diet, host-microbiome interactions, and other factors in the pathogenesis of FGIDs.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Case control study; Cohort profile; Functional gastrointestinal disorders; Irritable bowel syndrome; Observational study

Year:  2020        PMID: 32999886      PMCID: PMC7506285          DOI: 10.1159/000508160

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  59 in total

1.  The hospital anxiety and depression scale.

Authors:  R P Snaith; A S Zigmond
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-01

2.  Food-related gastrointestinal symptoms in the irritable bowel syndrome.

Authors:  M Simrén; A Månsson; A M Langkilde; J Svedlund; H Abrahamsson; U Bengtsson; E S Björnsson
Journal:  Digestion       Date:  2001       Impact factor: 3.216

Review 3.  Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome.

Authors:  Ana M González-Castro; Cristina Martínez; Eloísa Salvo-Romero; Marina Fortea; Cristina Pardo-Camacho; Teresa Pérez-Berezo; Carmen Alonso-Cotoner; Javier Santos; María Vicario
Journal:  J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 4.029

Review 4.  Smoking in Irritable Bowel Syndrome: A Systematic Review.

Authors:  Laura Sirri; Silvana Grandi; Eliana Tossani
Journal:  J Dual Diagn       Date:  2017-06-13

Review 5.  Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?

Authors:  K-A Gwee
Journal:  Neurogastroenterol Motil       Date:  2005-06       Impact factor: 3.598

6.  Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets.

Authors:  Bertalan Mesko; Szilard Poliska; Andrea Szegedi; Zoltan Szekanecz; Karoly Palatka; Maria Papp; Laszlo Nagy
Journal:  BMC Med Genomics       Date:  2010-05-05       Impact factor: 3.063

7.  U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact.

Authors:  D A Drossman; Z Li; E Andruzzi; R D Temple; N J Talley; W G Thompson; W E Whitehead; J Janssens; P Funch-Jensen; E Corazziari
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

Review 8.  Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome.

Authors:  Carla E Flik; Laura Bakker; Wijnand Laan; Yanda R van Rood; André J P M Smout; Niek J de Wit
Journal:  World J Gastroenterol       Date:  2017-03-28       Impact factor: 5.742

9.  The Oslo Health Study: The impact of self-selection in a large, population-based survey.

Authors:  Anne Johanne Søgaard; Randi Selmer; Espen Bjertness; Dag Thelle
Journal:  Int J Equity Health       Date:  2004-05-06

Review 10.  The epidemiology of irritable bowel syndrome.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Clin Epidemiol       Date:  2014-02-04       Impact factor: 4.790

View more
  2 in total

Review 1.  Nutrigenomics and Nutrigenetics Research in New Zealand, and Its Relevance and Application to Gastrointestinal Health.

Authors:  Lynnette Ferguson; Matthew Barnett
Journal:  Nutrients       Date:  2022-04-22       Impact factor: 6.706

2.  Two Gold Kiwifruit Daily for Effective Treatment of Constipation in Adults-A Randomized Clinical Trial.

Authors:  Simone B Bayer; Phoebe Heenan; Chris Frampton; Catherine L Wall; Lynley N Drummond; Nicole C Roy; Richard B Gearry
Journal:  Nutrients       Date:  2022-10-06       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.